发明名称 Pharmaceutical composition
摘要 A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboxylmide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied.
申请公布号 US8883794(B2) 申请公布日期 2014.11.11
申请号 US201414183283 申请日期 2014.02.18
申请人 Sumitomo Dainippon Pharma Co., Ltd. 发明人 Fujihara Kazuyuki
分类号 A61K31/497;C07D413/00;C07D417/00;C07D419/00;A61K31/496 主分类号 A61K31/497
代理机构 Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. 代理人 Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
主权项 1. An oral preparation comprising 20 to 120 mg of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboxylmide hydrochloride (lurasidone) of formula (1):a pregelatinized starch, a water-soluble excipient, a water-soluble polymer binder, a disintegrant, and a lubricant, wherein the content of lurasidone in the preparation is 20 to 45% (wt/wt), and the content of the pregelatinized starch in the preparation is 20 to 30% (wt/wt).
地址 Osaka JP